EIGR - Eiger BioPharmaceuticals GAAP EPS of -$0.41 revenue of $3.2M November, 09 2023 05:48 PM Eiger BioPharmaceuticals Inc. 2023-11-09 17:48:50 ET More on Eiger BioPharmaceuticals Eiger to stop late stage trial in hepatitis D patients, stock slumps ~36% after hours Seeking Alpha’s Quant Rating on Eiger BioPharmaceuticals For further details see: Eiger BioPharmaceuticals GAAP EPS of -$0.41, revenue of $3.2M